Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 7829-7835

  Liu, Jinyan ^a   Li, Hualin ^a   Justin Iampietro, M ^a   Barouch, Dan H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION PREVENTION; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION; VIRUS TRANSMISSION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; FEMALE; GENE PRODUCTS, GAG; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; MACACA MULATTA; MALE; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84864378857     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00512-12     Document Type: Article

References (41)

1. Abbink P, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Abel K. 2009. The rhesus macaque pediatric SIV infection model-a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr. HIV Res. 7:2-11.
3. Abel K, et al. 2006. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J. Virol. 80:6357-6367.
4. Allen TM, et al. 1998. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160:6062-6071.
5. Amara RR, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
6. Barouch DH, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203-5209.
7. Barouch DH, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
8. Borkowsky W, et al. 2000. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J. Infect. Dis. 181: 890-896.
9. Coovadia H. 2004. Antiretroviral agents-how best to protect infants from HIV and save their mothers from AIDS. N. Engl. J. Med. 351:289-292.
10. Coovadia HM, et al. 2007. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369:1107-1116.
11. De Cock KM, et al. 2000. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283:1175-1182.
12. Ferrantelli F, et al. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189:2167-2173.
13. Hansen SG, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
14. Haynes BF, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
15. Hofmann-Lehmann R, et al. 2001. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75:7470-7480.
16. Jackson JB, et al. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
17. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.
18. Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH. 2010. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J. Virol. 84:5986-5996.
19. Kuhn L, et al. 2008. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N. Engl. J. Med. 359:130-141.
20. Li H, et al. 2011. Durable mucosal simian immunodeficiency virusspecific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J. Virol. 85:11007-11015.
21. Liu J, et al. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82:4844-4852.
22. Liu J, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
23. Marthas ML, et al. 2011. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29:3124-3137.
24. Masek-Hammerman K, et al. 2010. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J. Virol. 84:9810-9816.
25. McFarland EJ, et al. 2001. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184:1331-1335.
26. McFarland EJ, et al. 2006. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 20:1481-1489.
27. Miller MD, Yamamoto H, Hughes AL, Watkins DI, Letvin NL. 1991. Definition of an epitope and MHC class I molecule recognized by gagspecific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147:320-329.
28. Nduati R, et al. 2000. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283:1167-1174.
29. Petra Study Team. 2002. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359: 1178-1186.
30. Pitcher CJ, et al. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29-43.
31. Reynolds MR, et al. 2005. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J. Virol. 79:9228-9235.
32. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, McClure HM. 2003. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 21:3370-3373.
33. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
34. Shetty AK, et al. 2003. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J. Acquir. Immune Defic. Syndr. 34:482-490.
35. Sun Y, et al. 2009. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J. Virol. 83:10596-10604.
36. Thomas TK, et al. 2011. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 8:e1001015. doi: 10.1371/journal.pmed.1001015.
37. Van Rompay KK, et al. 2010. Immunogenicity of viral vector, primeboost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 28: 1481-1492.
38. Van Rompay KK, et al. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38:124-134.
39. Van Rompay KK, et al. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177:1247-1259.
40. Van Rompay KK, et al. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77:179-190.
41. Veazey RS, et al. 2003. Simian immunodeficiency virus infection in neonatal macaques. J. Virol. 77:8783-8792.